Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
DexCom, Inc.
DXCM
NASDAQ·Healthcare·Medical - Devices·Mkt cap $26.6B
$71.35
▲ +3.62%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$54.11 - $89.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 17.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced proprietary CGM technology
- Strong intellectual property portfolio
- Strategic technology partnerships
- User-friendly digital health ecosystem
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Stable outlook
Global diabetes prevalence increase
Value
Significant premium - growth priced in
Momentum
Strong
+10.7% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying DXCM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
APR 30, 2026
Reported EPS of $0.56 vs $0.47 consensus (+19.1% surprise). Revenue of $1.2B vs $1.2B expected (+1.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+19.1%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+8%
+12%
+15%
+22%
+13%
+15%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.0B
$994.2M
$1.1B
$1.0B
$1.2B
$1.2B
$1.3B
$1.2B
Margins · last 8Q
Gross
62.9%
Operating
21.4%
Profit
16.7%
Wall Street consensus
13 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
0%
Sell
8%
Median Price Target
$78.50
▲ +10.0% vs $71.35
Latest: Deutsche Bank · Jun 23, 2026
6 analysts covering